{"url_path":"/sec/snse/8-k/2026-06-10/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-10","source_url":"https://www.sec.gov/Archives/edgar/data/1829802/0001193125-26-265879-index.html","accession_number":"0001193125-26-265879","cik":"0001829802","ticker":"FTH","issuer_name":"Faeth Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1829802/0001193125-26-265879-index.html","primary_entity_key":"0001829802","primary_entity_name":"Sensei Biotherapeutics, Inc."},"word_count":453,"has_tables":true,"body_markdown":"Item 5.07\n\nSubmission of Matters to a Vote of Security Holders.\n\nAt the Annual Meeting, the stockholders voted on six proposals, each of which is described in more detail in the Proxy Statement. Of the 1,341,140 shares outstanding as of the record date, 1,077,174 shares, or 80.32%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.\n\nProposal No. 1: Election of two nominees to serve as directors on the Board of Directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows:\n\n \n\nName\n  \nVotes For\n \n  \nVotes Withheld\n \n\nBob Holmen\n\n  \n \n741,993\n \n  \n \n23,529\n \n\nKristian Humer\n\n  \n \n741,275\n \n  \n \n24,247\n \n\nBroker Non-Votes: 311,652\n\nAll nominees were elected.\n\nProposal No. 2: Ratification of the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were cast as follows:\n\n \n\nVotes For\n\n \n\nVotes Against\n\n \n\nAbstained\n\n1,055,703\n \n3,879\n \n17,592\n\nProposal No. 2 was approved.\n\nProposal No. 3: Approval of the issuance of shares of the Company’s common stock upon conversion of the Company’s Series B Non-Voting Convertible Preferred Stock, which will (a) represent more than 20% of the shares of common stock outstanding and (b) result in the change of control of the Company pursuant to Nasdaq Listing Rules 5635(a) and 5635(b), respectively . The votes were cast as follows:\n\n \n\nVotes For\n\n \n\nVotes Against\n\n \n\nAbstained\n\n747,293\n \n3,397\n \n14,832\n\nBroker Non-Votes: 311,652\n\nProposal No. 3 was approved.\n\nProposal No. 4: Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended to date, to increase the number of authorized shares of our common stock from 12,500,000 to 300,000,000. The votes were cast as follows:\n\n \n\nVotes For\n\n \n\nVotes Against\n\n \n\nAbstained\n\n1,049,853\n \n10,485\n \n16,836\n\nBroker Non-Votes: —\n\nProposal No. 4 was approved.\n\nProposal No. 5: Approval of the 2026 Plan. The votes were cast as follows:\n\n \n\nVotes For\n\n \n\nVotes Against\n\n \n\nAbstained\n\n484,662\n \n266,010\n \n14,850\n\nBroker Non-Votes: 311,652\n\nProposal No. 5 was approved.\n\nProposal No. 6: Approval of the 2026 ESPP. The votes were cast as follows:\n\n \n\nVotes For\n\n \n\nVotes Against\n\n \n\nAbstained\n\n487,784\n \n262,910\n \n14,828\n\nBroker Non-Votes: 311,652\n\nProposal No. 6 was approved.\n\nProposal No. 7: Approval of the adjournment or postponement of the Annual Meeting, if necessary, to continue to solicit votes for Proposals Nos. 3, 4, 5 and/or 6 or if the Nasdaq initial listing application required by Nasdaq Listing Rule 5110(a) has not yet been approved.\n\nAs there were sufficient votes to approve Proposals Nos. 3, 4, 5 and 6 at the time of the Annual Meeting, Proposal No. 7 was not presented to stockholders."}